Discuss a Published Study’s Limitations With Care

A clinician getting ready for journal club stops you and asks whether a particular published study actually holds up. That question puts you in a strange spot. You did not run the study, you cannot rewrite it, and you should not act as its lawyer or its critic. Your job is to help the clinician read the paper clearly, see what the data support, and understand where the evidence stops.

Why This Conversation Goes Wrong

Most MSLs stumble here in one of two directions. The first is treating the question as a challenge to defend, especially if the study came from your own company. You start explaining away every limitation, and the conversation starts to sound like a sales pitch instead of a scientific exchange. The clinician notices immediately and trusts you less, not more.

The second failure runs the other way. You get so eager to prove you are objective that you pile on every flaw the paper has, and the exchange turns into a takedown. That is not balanced either. A study with a narrow population or a short follow up period can still be useful evidence. Your job is not to grade the paper pass or fail. It is to help the clinician see exactly what it can and cannot tell them.

Both failures share a root cause. You are answering the question the clinician did not ask. They rarely want your verdict on the paper. They want help thinking through it themselves, because they are the one who has to decide what it means for their practice.

This gets sharper when the study was sponsored by your own company. Some liaisons feel pressure to protect the company's investment in the trial, even though that is not part of the MSL role. Your credibility with a clinician rests on being seen as a scientific resource, not a commercial one. The moment a clinician suspects you are protecting the sponsor rather than describing the data, every future conversation with them gets harder.

How to Prepare

Read the paper again before the conversation, not just the abstract. Go straight to the limitations section the authors wrote themselves. That paragraph often names the exact concerns a sharp clinician will raise, and quoting the authors carries more weight than your own paraphrase. Check whether the result reached statistical significance and separately whether the effect size is large enough to matter to a practicing clinician. Those two questions get confused constantly, and a sharp clinician will ask about both.

Know four things cold before you sit down.

1. The population enrolled, including who was excluded and why.
2. The primary endpoint and whether it was patient centered or a surrogate marker.
3. The statistical plan, including whether the trial met its prespecified endpoint or relied on a subgroup or post hoc finding.
4. The funding source and any conflicts of interest disclosed in the paper.

Have the full publication and any supporting medical information document ready to send. If the clinician's real question turns out to touch use outside the approved label, stop and route it the way you would any unsolicited question, the way described in Handle an Unsolicited Scientific Question About Use Outside Approved Labeling. A journal club discussion can drift there fast once people start asking what a subgroup result means for a patient who does not fit the trial's population.

What to Say

Open by finding out what specifically worries the clinician, rather than launching into a summary of the whole paper.

You say, "That is worth digging into properly. We can look at the design, the population enrolled, and the limitations the authors themselves flagged. What part of the study is bothering you the most?"

The clinician says, "The exclusion criteria seem really narrow. Half my patients would not have qualified for this trial."

You say, "That is a fair read. The trial excluded patients with moderate renal impairment and anyone on more than three concurrent medications, so the population skews younger and healthier than a typical clinic population. The authors note that directly in their limitations section. I can send you the full paper along with our medical information letter so you can see the enrollment criteria in detail."

The clinician says, "So can I still use this to support switching my more complex patients?"

You say, "That is your clinical judgment to make, and it is exactly the kind of question this trial cannot answer on its own. What the trial shows is an effect in the population it enrolled. Whether that generalizes to a patient with renal impairment is a separate clinical decision, not something the data speak to directly."

Notice what happens in that exchange. You never say the study is good or bad. You name the limitation plainly, you back it with a specific detail rather than a vague gesture, and you hand the clinical conclusion back to the clinician instead of making it for them.

Mistakes to Avoid

Do not answer a request for a verdict with a verdict. If you say the study is strong or the study is weak, you have taken over the clinician's job of evaluating the evidence themselves.

Do not stay quiet about an unfavorable limitation because it feels uncomfortable to bring up. If the clinician cites the trial in a talk next month without knowing about the narrow exclusion criteria, that reflects on the credibility of the data and on your credibility as a source.

Do not bury the clinician in statistical terms to sound thorough. A dense explanation of confidence intervals and hazard ratios can feel like evasion even when it is accurate. Explain the limitation in plain terms first, then offer the technical detail if they want it.

Do not turn a discussion of a paper's population into an answer about how the product should be used in patients outside that population. That question belongs in a different lane, the one covered in Route an Unsolicited Scientific Question With Care. Keep the two separate even when the clinician blends them into one question.

Do not use the words this proves or this shows that treatment works better. A single study, even a well designed one, supports a finding under specific conditions. It does not prove a general clinical rule.

How to Practice and Score It

A manager can run this as a role play with three variations of the same reader. One clinician wants a quick yes or no on whether to trust the paper. One is skeptical of anything sponsored by a manufacturer. One has already decided the study is flawed and wants you to agree with them so they can dismiss it. Each version pulls you toward giving an opinion you should not give.

Score the exchange on three things. Did the MSL identify the actual concern before responding, instead of reciting a rehearsed summary. Did the MSL name at least one real limitation clearly and specifically, with a detail rather than a hedge. Did the closing statement separate what the paper found from what the clinician should do with a patient, leaving that judgment with the clinician.

Debrief on the moment where the temptation to give a verdict was strongest, because that is where most liaisons slip after they have already handled the easy part of the conversation well. DealSpeak's Pharmaceuticals practice conversations library includes this scenario alongside other journal club and unsolicited question exchanges, so a new liaison can run it more than once before facing it with a real clinician.

Handled well, this conversation does not end with the clinician agreeing with you. It ends with them reading the next paper a little more carefully on their own. That habit outlasts any single study and it is the real measure of a good scientific exchange.